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Abstract 
Objective: Data on circulating total antioxidant capacity (TAC) levels in ischemic stroke patients compared with 
healthy controls are limited and provided conflicting findings. There are not data about the association between 
circulating TAC levels, peroxidation state and outcome in patients with severe ischemic stroke. The objective of this 
study was to examine the relationship of TAC with 30‑day mortality after severe ischemic stroke.
Methods:  This multicenter study included 58 patients with coma (Glasgow Coma Scale < 9) following severe 
malignant middle cerebral artery infarction (MMCAI). We measured circulating levels of TAC and malondialdehyde 
(MDA, a biomarker of lipid peroxidation) on day 1 of severe MMCAI diagnosis. The study endpoint was 30‑day 
mortality.
Results: Non‑survivors (n = 29) showed higher serum TAC levels (p < 0.001) and higher serum MDA levels (p = 0.004) 
than survivors (n = 29). Multiple binomial logistic regression analysis showed that serum TAC levels were associated 
with 30‑day mortality, after controlling for Glasgow Coma Scale and age (odds ratio 1.92; 95 % confidence interval 
1.201–3.072; p = 0.006). There was a correlation between serum TAC and MDA levels (rho = 0.35; p = 0.008).
Conclusions: This single‑center study in severe MMCAI patients found an association between higher serum TAC 
levels and 30‑day mortality and further identified a relationship between serum TAC levels, lipid peroxidation state 
and mortality after severe ischemic stroke.
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Background
Ischemic stroke leads to substantial disability, mortal-
ity and consumption of resources [1]. Increased reactive 
oxygen species (ROS) appears during ischemic stroke 
and are involved in cellular damage [2–8]. Antioxidant 
state may eventually be overwhelmed leading to oxidative 
stress, thereby exacerbating damage to proteins, lipids, 
carbohydrates and nucleic acids [2–8]. The different anti-
oxidant agents act synergistically to cause further dam-
age; thus, the determination of total antioxidant capacity 
(TAC) in serum or plasma could give more information 
about the antioxidant status than the determination of 
individual antioxidant compounds [9].
Circulating TAC in ischemic stroke patients has been 
scarcely studied, and the findings are conflicting [10–
15]. In some studies, it was found that circulating TAC 
in ischemic stroke patients was lower than in healthy 
control subjects [10–13], while in another study no dif-
ferences in circulating TAC between ischemic stroke 
patients and healthy control subjects were found [14]. 
Finally, in another study was found higher circulating 
TAC in ischemic stroke patients than in healthy control 
subjects [15]. However, there are not data about the asso-
ciation between circulating TAC levels, peroxidation state 
and mortality in patients with ischemic stroke. Thus, the 
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objective of this study was to determine whether there is 
an association between circulating TAC levels, peroxida-
tion state and mortality in patients with severe malignant 
middle cerebral artery infarction (MMCAI).
Methods
Design and patients
This multicenter, observational, prospective study 
included patients with severe malignant middle cer-
ebral artery infarction (MMCAI). We used Glasgow 
Coma Scale (GCS) to assess the severity of MMCAI [16]. 
Comatose patients defined by a GCS lower than 9 were 
included. Patients with age less than 18 years, pregnancy, 
malignant or inflammatory disease were excluded.
The study was carried out in six Spanish intensive care 
units and was approved by the institutional review board 
of each participant hospitals: Hospital Universitario 
Nuestra Señora de Candelaria (Santa Cruz de Tenerife, 
Spain), Hospital Universitario de Canarias (La Laguna, 
Santa Cruz de Tenerife, Spain), Hospital Clínico Univer-
sitario de Valencia (Valencia, Spain), Hospital General de 
La Palma (La Palma, Spain), Hospital Universitario Dr. 
Negrín (Las Palmas de Gran Canaria, Spain) and Hospi-
tal Insular (Las Palmas de Gran Canaria, Spain). In addi-
tion, the written informed consent was obtained from 
legal representatives of the patients.
Previously, we determined serum malondialdehyde 
(MDA) levels (to assess the level of lipid peroxidation) in 
that cohort of patients with severe MMCAI [17]. In the 
current analysis, we have examined the association of 
serum TAC levels with mortality.
Variables recorded
For each patient, the following variables were recorded: 
activated partial thromboplastin time (aPTT), age, 
Acute Physiology and Chronic Health Evaluation II 
(APACHE II) score [18], bilirubin, creatinine, decom-
pressive craniectomy, fibrinogen, GCS, glycemia, hemo-
globin, international normalized ratio (INR), lactic acid, 
leukocytes, pressure of arterial oxygen (PaO2), frac-
tion inspired oxygen (FiO2) ratio, platelets, sex, sodium 
and temperature. The endpoint of the study was 30-day 
mortality.
Blood sample collection
We collected blood samples in tubes with separator gel 
on day 1 of severe MMCAI diagnosis. We considered day 
1 as the day that patients showed GCS < 9. Blood sam-
ples were obtained within the first 4 h of severe MMCAI 
diagnosis. We obtained serum samples by centrifugation 
at 1000×g for 15 min after coagulation during 10 min at 
room temperature. Then, the serum samples were ali-
quoted and frozen, until determination, at −80 °C.
Determination of serum TAC levels
We determined TAC in serum samples using antioxidant 
assay kit (Cayman Chemical Corporation, Ann Arbor, 
USA). The assay is based on the ability to inhibit the oxi-
dation of ABTS® (2,2′-azino-di-[3-ethylbenzthiazoline 
sulfonate]) to ABTS®+ by metmyoglobin by antioxidants 
of the serum sample. The antioxidant capacity from the 
serum sample to prevent ABTS oxidation is compared 
with that by Trolox (a water-soluble tocopherol analog) 
and was quantified as molar Trolox equivalents. We 
assayed all samples, following manufacturer’s instruc-
tions, in duplicate at 20-fold dilutions in assay buffer. 
Absorbances at 750  nm using the EnSpire multimode 
plate reader (PerkinElmer, Waltham, MA, USA) were 
measured. Serum TAC levels were expressed in mmol/L. 
The assay detection limit was of 0.04  mmol/L; and the 
inter- and intra-assay coefficient of variation (CV) was 
3.0 and 3.4 %, respectively. All serum samples were pro-
cessed at the same time, at the end of the recruitment 
process, to avoid the possible dispersion of results. A 
laboratory technician blinded to all clinical data of the 
Laboratory Deparment of the Hospital Universitario de 
Canarias (La Laguna, Tenerife, Spain) processed all the 
samples.
Determination of serum malondialdehyde (MDA) levels
To asses lipid peroxidation, serum MDA levels were 
measured [19]. MDA is an end product formed during 
degradation of cellular membrane phospholipids due 
to lipid peroxidation, after is released into extracellular 
space and the blood.
We determined serum MDA levels by thiobarbitu-
ric acid-reactive substance (TBARS) method described 
by Kikugawa et  al. [20]. We use n-butanol to remove 
the pink complex samples. We placed each sample in 
a 96-well plate and read it in a microplate spectropho-
tometer reader (Benchmark Plus, Bio-Rad, Hercules, 
CA, USA) at 535  nm. The assay detection limit was of 
0.079  nmol/ml. The inter- and intra-assay CV was 4.01 
and 1.82  %, respectively. Serum MDA concentrations 
were expressed in nmol/ml. All serum samples were pro-
cessed at the same time, at the end of the recruitment 
process, to avoid the possible dispersion of results. A 
laboratory technician blinded to all clinical data of the 
Department of Physiology, Faculty of Medicine (Univer-
sity of the La Laguna, Santa Cruz de Tenerife, Spain), 
processed all the samples.
Statistical methods
We reported categorical variables as frequencies and 
percentages, and we carried out comparisons between 
groups using Chi-square test. We reported continu-
ous variables as medians and interquartile ranges, and 
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we carried out comparisons between groups using Wil-
coxon–Mann–Whitney test.
Goodness of fit for serum TAC levels to predict 30-day 
mortality was carried out with a receiver operating char-
acteristic (ROC) analysis. We performed a Kaplan–Meier 
of survival analysis, using serum TAC lower/higher than 
3.39 mmol/mL as the independent variable and survival 
at 30  days as the dependent variable; and both curves 
were compared by log-rank test. We used Youden’s index 
to select the cutoff point for serum TAC levels.
We used multiple logistic regression analysis to deter-
mine the association between serum TAC levels and 
30-day mortality, controlling for GCS and age. We calcu-
lated odds ratio and 95 % confidence intervals to measure 
the clinical impact of the predictor variables. The associa-
tion between continuous variables was carried out using 
Spearman’s rank correlation test.
We performed statistical analyses using SPSS 17.0 
(SPSS Inc., Chicago, IL, USA), NCSS 2000 (Kaysville, 
Utah) and LogXact 4.1, (Cytel Co., Cambridge, MA). 
All p values less than 0.05 were considered statistically 
significant.
Results
Table  1 shows the comparisons between survivors 
(N = 29) and non-survivors (N = 29) MMCAI patients. 
Non-survivors had lower GCS (p = 0.02), higher serum 
TAC levels (p  <  0.001) and higher serum MDA levels 
(p = 0.004) than survivors (Figs. 1, 2). No patient under-
went endovascular thrombectomy.
We found that the area under the curve (AUC) for 
serum TAC levels as predictor of 30-day mortality was of 
0.82 (95 % CI 0.70–0.91; p < 0.001) (Fig. 3).
Table 1 Comparison between survivor and non-survivor severe MMCAI patients
p percentile, PaO2 pressure of arterial oxygen, FIO2 pressure of arterial oxygen/fraction inspired oxygen, INR international normalized ratio, aPTT activated partial 
thromboplastin time, APACHE II Acute Physiology and Chronic Health Evaluation II, TAC total antioxidant capacity
Survivors (n = 29) Non-survivors (n = 29) p value
Sex female—n (%) 13 (44.8) 11 (37.9) 0.79
Age (years)—median (p 25–75) 57 (47–67) 64 (54–70) 0.08
Temperature (°C)—median (p 25–75) 36.4 (35.8–37.0) 37.0 (36.0–37.6) 0.18
C‑reactive protein (mg/L)—median (p 25–75) 19 (5–45) 27 (12–48) 0.39
Timing of coma—n (%) 0.97
 At hospital admission 19 (65.5) 20 (69.0)
 Within first 24 h of hospital admission 5 (17.2) 5 (17.2)
 24–48 h of hospital admission 1 (3.4) 1 (3.4)
 48–96 h of hospital admission 2 (6.9) 2 (6.9)
 More than 96 h of hospital admission 2 (6.9) 1 (3.4)
Thrombolysis—n (%) 10 (34.5) 9 (31.0) 0.99
Decompressive craniectomy—n (%) 8 (27.6) 5 (17.2) 0.53
Sodium (mEq/L)—median (p 25–75) 139 (136–145) 140 (139–146) 0.41
Glycemia (g/dL)—median (p 25–75) 128 (100–170) 135 (105–160) 0.99
Leukocytes × 103/mm3—median (p 25–75) 12.5 (9.5–16.9) 13.9 (9.3–21.4) 0.43
PaO2 (mmHg)—median (p 25–75) 137 (104–207) 114 (86–153) 0.26
PaO2/FiO2 ratio—median (p 25–75) 300 (197–372) 248 (184–330) 0.23
Bilirubin (mg/dl)—median (p 25–75) 0.70 (0.40–0.95) 0.70 (0.33–1.10) 0.87
Creatinine (mg/dl)—median (p 25–75) 0.80 (0.60–1.15) 1.00 (0.76–1.28) 0.12
Hemoglobin (g/dL)—median (p 25–75) 12.2 (11.4–14.4) 13.7 (11.0–14.9) 0.78
Glasgow Coma Scale score—median (p 25–75) 7 (6–8) 6 (3–7) 0.02
Lactic acid (mmol/L)—median (p 25–75) 1.30 (0.90–1.70) 1.40 (1.00–2.10) 0.25
Platelets × 103/mm3—median (p 25–75) 214 (170–280) 170 (131–212) 0.008
INR—median (p 25–75) 1.09 (1.01–1.20) 1.20 (1.05–1.31) 0.10
aPTT (seconds)—median (p 25–75) 28 (26–30) 27 (26–32) 0.77
Fibrinogen (mg/dl)—median (p 25–75) 440 (335–494) 419 (311–631) 0.82
APACHE II score—median (p 25–75) 20 (16–26) 22 (19–28) 0.22
Malondialdehyde (nmol/mL)—median (p 25–75) 1.90 (1.24–2.42) 2.93 (1.83–3.77) 0.004
TAC (mmol/mL)—median (p 25–75) 2.38 (1.83–3.35) 5.33 (3.27–11.40) <0.001
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In the survival analysis, patients with serum TAC 
higher than 3.39 mmol/mL had higher 30-day mortality 
than patients with lower serum TAC levels (hazard ratio 
4.5; 95 % CI 2.09–9.45; p < 0.001) (Fig. 4).
We found in the multiple binomial logistic regression 
analysis that serum TAC levels were associated with 
30-day mortality (odds ratio 1.92; 95  % CI 1.201–3.072; 
p = 0.006) after adjusting for GCS and age (Table 2).
We also found a correlation between serum TAC and 
MDA levels (rho = 0.35; p = 0.008).
Discussion
The main finding of our study was that in severe MMCAI 
patients non-survivors had higher serum TAC levels than 
survivors and that serum TAC levels could be used as a 
prognostic biomarker of mortality in MMCAI patients. 
We also found an association between serum TAC levels 
and lipid peroxidation state in severe MMCAI patients. 
Previously, some studies compared circulating TAC 
between ischemic stroke patients and healthy subjects, 
and there were found conflicting findings [10–15]. In our 
Fig. 1 Dot plot of serum total antioxidant capacity (TAC) levels in 
survivors and non‑survivors at 30 days
Fig. 2 Dot plot of serum malondialdehyde levels in survivors and 
non‑survivors at 30 days
Fig. 3 Receiver operation characteristic analysis using serum total 
antioxidant capacity (TAC) as predictor of mortality at 30 days
Fig. 4 Survival curve at 30 days using 3.39 nmol/mL of serum total 
antioxidant capacity (TAC) as cutoff
Table 2 Multiple binomial logistic regression analysis 
to predict 30-day mortality
Variable Odds ratio 95 % confidence 
interval
p
Glasgow Coma  
Scale (points)
0.69 0.478–0.997 0.048
Age (years) 1.02 0.964–1.077 0.51
Serum TAC levels 
(mmol/mL)
1.92 1.201–3.072 0.006
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study, we found higher serum TAC levels in non-surviv-
ing than in surviving severe MMCAI patients for the first 
time. In addition, according to the results of the multi-
ple logistic regression analysis, there was an association 
between circulating TAC levels and mortality in patients 
with severe MMCAI; and that may be the major novel 
finding of our study.
Some studies reported lower circulating TAC and 
higher circulating MDA levels in ischemic stroke patients 
than in healthy control subjects [10, 13]. However, in 
one study higher circulating TAC and nitric oxide levels 
in ischemic stroke patients than in healthy control sub-
jects were found [15]. Furthermore, higher circulating 
hydroperoxides and a tendency to higher circulating TAC 
levels in ischemic stroke patients compared with healthy 
control subjects were observed [14]. The findings of our 
study are in line with some of those previous studies [14, 
15]. However, while previous studies compared circu-
lating TAC levels between ischemic stroke patients and 
healthy control subjects, in the present analysis we com-
pared circulating TAC levels between non-survivors and 
survivor patients with severe ischemic stroke.
In addition, the findings of our study are in line with 
the results of other studies showing higher circulat-
ing TAC levels in non-survivor compared with survivor 
patients, and an association between circulating TAC 
levels and patient mortality, such as in septic patients 
[21] and traumatic brain injury patients [22]. We report 
for the first time that serum TAC levels could be used as 
a predictor biomarker of mortality in patients with severe 
MMCAI according to the results of ROC curve analysis. 
In addition, the other novel aspect of our study was the 
positive association between serum TAC levels and lipid 
peroxidation (assessed by serum MDA levels).
The association that we have found between increased 
serum TAC levels and mortality in patients with severe 
MMCAI could seem initially counterintuitive because 
improved protection against oxidative processes would 
instead protect the brain against reactive oxygen species 
(ROS)-induced damage. However, we think that the find-
ings of previous studies showing a higher oxidative state 
in patients with ischemic stroke compared with healthy 
control subjects [10, 13–15], and the findings of our study 
showing higher circulating TAC and MDA levels in non-
survivors compared to survivors patients with severe 
MMCAI could reflect that there is an oxidative state in 
stroke and that it is higher in non-surviving patients. We 
postulate that non-surviving MMCAI patients display 
higher serum TAC levels to compensate the higher ROS 
production, as it was observed by our group in severe sep-
tic patients [21] and in patients with severe traumatic brain 
injury [22]; thus, non-surviving patients showed higher 
serum levels of TAC and MDA than surviving patients.
From a therapeutic perspective, the development of 
antioxidant agents could be used as a new class of drugs 
for the treatment of patients with MMCAI. The use of 
melatonin has reduced circulating MDA levels and mor-
tality rate in asphyxiated newborns patients [23] and 
septic newborns patients [24]. The administration of dif-
ferent antioxidant agents (vitamins E and C, zinc sulfate, 
allopurinol, melatonin and N-acetylcysteine) has reduced 
circulating MDA levels and mortality rate in burn 
patients [25]. The use of amantadine sulfate has reduced 
MDA levels and mortality in traumatic brain injury 
patients [26]. The administration of different antioxidant 
vitamins (E, C, B2, B6, B9 and B12) in acute ischemic 
stroke patients has been associated with a reduction in 
circulating MDA levels [27].
Some limitations should be recognized in our study. 
First, we did not determine serum TAC levels in healthy 
control subjects; however, the objective of our study was 
not to determine whether there is difference between 
ischemic stroke patients and healthy control subjects, 
but rather the association between serum TAC levels and 
mortality. Second, we did not measure serum TAC levels 
in patients with middle cerebral artery infarction without 
malignant criteria. Third, we did not determine serum 
TAC levels during follow-up. Fourth, we have found a 
higher variability (4.3 %) in serum TAC levels that men-
tioned by the manufacturer (3.4  %); however, our vari-
ability is acceptable. Fifth, the sensitivity and specificity 
of serum TAC levels as prognostic biomarker of mortal-
ity were not very high; however, both were statistically 
significant. We think that the sole use of serum TAC lev-
els as prognostic biomarker of mortality in patients with 
severe malignant MMCAI should be taken with caution. 
Sixth, we did not report the National Institutes of Health 
Stroke Scale (NIHSS) due to the difficulty to evaluate the 
different items of this scale in our patients with GCS < 9. 
Seventh, the rate of decompressive craniectomy in our 
series was relatively low (22.4  %), although in line with 
published series [28–30]. Pending further larger studies, 
we believe that the findings of our study could open the 
way for future research on TAC and oxidative stress in 
ischemic stroke patients.
Conclusions
Higher serum TAC levels are associated with mortality in 
patients with severe ischemic stroke and could be used as 
a prognostic biomarker of outcome.
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